Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

被引：18

作者：

George, Daniel J. ^{[1
]}

Hessel, Colin ^{[2
]}

Halabi, Susan ^{[3
,4
]}

Michaelson, M. Dror ^{[5
]}

Hahn, Olwen ^{[6
]}

Walsh, Meghara ^{[7
]}

Picus, Joel ^{[8
]}

Small, Eric J. ^{[9
]}

Dakhil, Shaker ^{[10
]}

Feldman, Darren R. ^{[11
]}

Mangeshkar, Milan ^{[2
]}

Scheffold, Christian ^{[2
]}

Morris, Michael J. ^{[11
]}

Choueiri, Toni K. ^{[7
]}

机构：

[1] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA

[2] Exelixis Inc, Alameda, CA USA

[3] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA

[4] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA

[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[6] Alliance Protocol Operat Off, Chicago, IL USA

[7] Dana Farber Partners CancerCare, Boston, MA USA

[8] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[9] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Univ Kansas Wichita, Wichita, KS USA

[11] Memorial Sloan Kettering Canc Ctr, New York, NY USA

来源：

ONCOLOGIST | 2019年 / 24卷 / 11期

关键词：

THERAPY;

D O I：

10.1634/theoncologist.2019-0316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number. NCT01835158.

引用

页码：1497 / 1501

页数：5

共 50 条

[1] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Choueiri, Toni K.
Halabi, Susan
Sanford, Ben L.
Hahn, Olwen
Michaelson, M. Dror
Walsh, Meghara K.
Feldman, Darren R.
Olencki, Thomas
Picus, Joel
Small, Eric J.
Dakhil, Shaker
George, Daniel J.
Morris, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 591 - +
[2] CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial
Choueiri, T. K.
Halabi, S.
Sanford, B.
Hahn, O.
Michaelson, M. D.
Walsh, M.
Olencki, T.
Picus, J.
Small, E. J.
Dakhil, S.
George, D.
Morris, M. J.
ANNALS OF ONCOLOGY, 2016, 27
[3] Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
George, Daniel J.
Hessel, Colin
Halabi, Susan
Sanford, Ben L.
Michaelson, M. Dror
Hahn, Olwen Mary
Walsh, Meghara K.
Olencki, Thomas
Picus, Joel
Small, Eric Jay
Dakhil, Shaker R.
Feldman, Darren R.
Mangeshkar, Milan
Scheffold, Christian
Morris, Michael J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[4] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (vol 35, pg 591, 2017)
Choueiri
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (32) : 3736 - 3736
[5] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (vol 35, pg 591, 2017)
不详
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05) : 521 - 521
[6] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Choueiri, Toni K.
Hessel, Colin
Halabi, Susan
Sanford, Ben
Michaelson, M. Dror
Hahn, Olwen
Walsh, Meghara
Olencki, Thomas
Picus, Joel
Small, Eric J.
Dakhil, Shaker
Feldman, Darren R.
Mangeshkar, Milan
Scheffold, Christian
George, Daniel
Morris, Michael J.
EUROPEAN JOURNAL OF CANCER, 2018, 94 : 115 - 125
[7] 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' (vol 94, pg 115, 2018)
Choueiri, Toni K.
Hessel, Colin
Halabi, Susan
Sanford, Ben
Michaelson, M. Dror
Hahn, Olwen
Walsh, Meghara
Olencki, Thomas
Picus, Joel
Small, Eric J.
Dakhil, Shaker
Feldman, Darren R.
Mangeshkar, Milan
Scheffold, Christian
George, Daniel
Morris, Michael J.
EUROPEAN JOURNAL OF CANCER, 2018, 103 : 287 - 287
[8] ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).
Feldman, Darren R.
Feuilly, Marion
Meng, Jie
Lister, Johanna
Marteau, Florence
Morris, Michael J.
George, Daniel J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).
Chen, Ronald C.
Feuilly, Marion
Meng, Jie
Lister, Johanna
Marteau, Florence
Morris, Michael J.
George, Daniel J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Choueiri, T. K.
Hessel, C.
Halabi, S.
Sanford, B.
Hahn, O.
Michaelson, M. D.
Walsh, M.
Olencki, T.
Picus, J.
Small, E. J.
Dakhil, S.
Scheffold, C.
George, D. J.
Morris, M. J.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →